Trial · NCT07483801
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
NCT07483801, Phase 4, Not yet recruiting, Cambridge University Hospitals NHS Foundation Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies. Trials, record NCT07483801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07483801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
- NCT number
- NCT07483801
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 112 participants, estimated
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Conditions
- Cardiovascular Diseases
- Interventions
- semaglutide, Tirzepatide
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1A: Change in forearm blood flow parameters after infusion of semaglutide (Percentage Change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Percent Change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Percentage change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Blood pressure) | 2-2.5 months from screening to follow-up | Blood pressure measured in mmHg |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07483801
GET https://conductscience.org/api/trials/v1/NCT07483801/registered?page=2